Why JanOne Shares Are Trading Higher Today
Why JanOne Shares Are Trading Higher Today
Janone股价今日为何走高
- JanOne Inc (NASDAQ:JAN) sold all of the assets, and none of the liabilities, of GeoTraq Inc., its wholly-owned subsidiary, to SPYR Inc (OTC:SPYR) for an aggregate of $13.5 million.
- The purchase price is payable in cash and shares of SPYR's common stock.
- SPYR issued 30 million shares of its common stock and delivered a five-year Promissory Note to JanOne in the initial principal amount of $12.6 million. The Promissory Note bears simple interest at an annual rate of 8% and delivers quarterly interest payments in arrears.
- "We believe this transaction further allows us to focus on our main business. Right now, our priority is the development of drugs with non-addictive, pain-relieving properties, specifically JAN101 (formerly known as TV1001SR), which is a potential treatment for peripheral artery disease (PAD). This sale of our subsidiary will help us continue to fund the necessary clinical trials for JAN101," commented Tony Isaac, CEO of JanOne.
- Price Action: JAN shares are trading higher by 83% at $4.10 and SPYR lower by 9.87% at $0.03 on the last check Tuesday.
- Janone Inc.(纳斯达克股票代码：JAN)将其全资子公司GeoTraq Inc.的所有资产，而不是任何负债出售给SPYR Inc.(场外交易：SPYR)，总计1350万美元。
- 收购价格以现金和SPYR普通股的股票支付。
- SPYR发行了3000万股普通股，并向Janone交付了一张五年期本票，初始本金为1260万美元。本票的单息年利率为8%，每季度支付一次拖欠利息。
- Janone首席执行官托尼·艾萨克评论道：“我们相信，这笔交易将使我们进一步专注于我们的主业。目前，我们的首要任务是开发具有非成瘾性、止痛性的药物，特别是JAN101(以前称为TV1001SR)，这是一种治疗外周动脉疾病(PAD)的潜在药物。此次出售我们的子公司将帮助我们继续为JAN101提供必要的临床试验资金。”
- 价格行动：在周二的最后一次检查中，Jan的股价上涨了83%，至4.10美元，SPYR下跌了9.87%，至0.03美元。